We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+51.8%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$360M
AUM Growth
+$24.1M
Cap. Flow
-$34.5M
Cap. Flow %
-9.57%
Top 10 Hldgs %
41.39%
Holding
100
New
33
Increased
9
Reduced
32
Closed
23

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$11.1M
2
RNAM
Avidity Biosciences
RNAM
+$7.67M
3
CATX icon
Perspective Therapeutics
CATX
+$6.91M
4
SLDB icon
Solid Biosciences
SLDB
+$6.83M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$6.54M

Top Sells

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$13.7M
2
MGNX icon
MacroGenics
MGNX
+$11.8M
3
MDT icon
Medtronic
MDT
+$11.1M
4
SNY icon
Sanofi
SNY
+$10.9M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.04%
2 Miscellaneous 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$25.5M 7.08%
566,287
-79,294
-12% -$3.22M
SLDB icon
2
Solid Biosciences
SLDB
$1.05B
$17.6M 4.9%
1,325,065
+730,210
+123% +$6.83M
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$17M 4.73%
483,972
-16,070
-3% -$539K
ORIC icon
4
Oric Pharmaceuticals
ORIC
$1.37B
$15.3M 4.25%
1,113,007
-56,993
-5% -$677K
MRSN
5
DELISTED
Mersana Therapeutics
MRSN
$13.3M 3.69%
118,752
-138,053
-54% -$13.7M
CLDX icon
6
Celldex Therapeutics
CLDX
$3.07B
$12.6M 3.49%
299,316
+52,101
+21% +$2.14M
RNAM
7
DELISTED
Avidity Biosciences
RNAM
$12.5M 3.47%
+489,303
New +$7.67M
NUVL
8
DELISTED
Nuvalent
NUVL
$11.8M 3.29%
157,750
-35,250
-18% -$2.81M
CCCC icon
9
C4 Therapeutics
CCCC
$474M
$11.7M 3.26%
+1,435,931
New +$11.1M
PRAX icon
10
Praxis Precision Medicines
PRAX
$9.63B
$11.6M 3.23%
190,556
-93,285
-33% -$4.18M
PSTX
11
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$11.5M 3.19%
3,596,476
-109,303
-3% -$364K
AKRO
12
DELISTED
Akero Therapeutics
AKRO
$10.1M 2.81%
399,949
+150,695
+60% +$3.62M
CATX icon
13
Perspective Therapeutics
CATX
$355M
$9.65M 2.68%
+810,811
New +$6.91M
RYTM icon
14
Rhythm Pharmaceuticals
RYTM
$7.38B
$7.96M 2.21%
183,776
+9,528
+5% +$417K
ALPN
15
DELISTED
Alpine Immune Sciences Inc
ALPN
$7.89M 2.19%
199,020
-98,769
-33% -$2.91M
URGN icon
16
UroGen Pharma
URGN
$2.13B
$7.63M 2.12%
508,587
-16,817
-3% -$275K
GOSS icon
17
Gossamer Bio
GOSS
$83.2M
$7.23M 2.01%
6,130,268
– –
MGNX icon
18
MacroGenics
MGNX
$263M
$7.04M 1.95%
478,079
-780,562
-62% -$11.8M
COGT icon
19
Cogent Biosciences
COGT
$6.02B
$6.97M 1.93%
1,036,667
+69,919
+7% +$432K
KALV
20
DELISTED
KalVista Pharmaceuticals
KALV
$6.66M 1.85%
561,183
+449,449
+402% +$5.99M
KOD icon
21
Kodiak Sciences
KOD
$2.37B
$6.52M 1.81%
1,238,822
+238,822
+24% +$1.17M
VCYT icon
22
Veracyte
VCYT
$3.48B
$6.22M 1.73%
280,773
+33,050
+13% +$806K
CRNX icon
23
Crinetics Pharmaceuticals
CRNX
$9B
$5.98M 1.66%
+127,835
New +$5M
OLMA icon
24
Olema Pharmaceuticals
OLMA
$899M
$5.83M 1.62%
515,317
-58,513
-10% -$755K
BBOT
25
BridgeBio Oncology
BBOT
$701M
$5.2M 1.44%
+500,000
New +$5.18M
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Silverarc Capital Management held 100 positions worth $360M, up 7.2% from $336M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Silverarc Capital Management withdrew a net $34.5M in Q1 2024, closing 23 positions and reducing 32 holdings. Its most notable exit was Medtronic, an estimated $11.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

Against the trend, Silverarc Capital Management opened a new position in C4 Therapeutics worth $11.7M.

  • Silverarc Capital Management's largest Q1 2024 buy was C4 Therapeutics: 1,435,931 shares worth $11.7M.
  • Silverarc Capital Management added most to Solid Biosciences in Q1 2024, an estimated $6.83M increase.
  • Silverarc Capital Management's biggest Q1 2024 reduction was Mersana Therapeutics, cutting an estimated $13.7M.
  • Silverarc Capital Management fully exited Medtronic in Q1 2024, selling an estimated $11.1M.
  • Silverarc Capital Management's ten largest holdings make up 41% of its $360M portfolio in Q1 2024.
  • Silverarc Capital Management opened 33 new positions and closed 23 in Q1 2024.
  • Silverarc Capital Management's portfolio value rose 7.2% quarter-over-quarter to $360M.

Based on Silverarc Capital Management's 13F filing for Q1 2024, filed 15 May 2024.